Geriatric oncology: challenges for the new century

The management of cancer in the older aged person represents one of the maj or immediate challenges of medicine. The response to this challenge involve s answers to the following questions: 1. Who is old? Currently, 70 years of age may be considered the lower limit of senescence because the majority of age-related changes occur after this age. Individual estimates of life expectancy and functional reserve may be obtained by a comprehensive and time-consuming multidimensional geriatric assessment. The current instrument may be fine-tuned and new instruments, i ncluding laboratory tests of ageing, may be developed. 2. Why do older persons develop more cancer? It is clear that ageing tissue s are more susceptible to late-stage carcinogen. Older persons may represen t a natural monitor system for new environmental carcinogens, and may also represent a fruitful ground to study the late stages of carcinogenesis. 3. Is cancer different in younger and older persons? Clearly, the behaviour of some tumours, including acute myeloid leukaemia, non-Hodgkin's lymphoma and breast cancer change with the age of the patient. The mechanisms of th ese changes that may involve both the tumour cell and the tumour host are p oorly understood. 4. Can cancer be prevented in older individuals? Chemoprevention offers a n ew horizon of possibilities for cancer prevention; older persons may benefi t most from chemoprevention due to increased susceptibility to environmenta l carcinogens. Screening tests may become more accurate in older individual s due to increased prevalence of cancer, but may be less beneficial due to more limited patient life expectancy. 5. Do older persons benefit from cytotoxic treatment? The answer to this qu estion partly stands on proper patient selection, partly on the development of safer forms of cancer treatment and prudent use of antidotes to chemoth erapy toxicity. 6. What is the cost of treating older cancer patients? The treatment of old er patients is generally more costly. This cost should be assessed against the cost of not treating cancer and promoting functional dependence, which by itself is extremely costly. 7. What are the endpoints of clinical trials in older cancer patients? With more limited life expectancy, the effect of treatment on quality of life i s paramount. Reliable assessment of quality of life is essential for interp reting clinical trials in older individuals. (C) 2000 Elsevier Science Ltd. All rights reserved.